- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Medicus Pharma Ltd. - 10-K/A, Annual Report | - | SEC Filings | ||
| MEDICUS PHARMA Aktie jetzt für 0€ handeln | |||||
| Mo | Medicus Pharma Ltd: Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill | 6 | GlobeNewswire (USA) | ||
| 24.04. | Medicus Pharma Ltd. - 8-K, Current Report | - | SEC Filings | ||
| 18.04. | New to The Street to Broadcast Tonight on Bloomberg at 6:30 PM EST - Show #744 Featuring Virtuix Holdings, Neonc Technologies Holdings, Medicus Pharma, YY Group Holding, and Vivos Therapeutics | 662 | ACCESS Newswire | The show also broadcasts as sponsored programming additionally across MENA and Latin America as "Nuevo En La Calle," reaching millions of households worldwide weekly, with expanded digital distribution... ► Artikel lesen | |
| 17.04. | Medicus Pharma submits orphan drug application for skin cancer treatment | 2 | Investing.com | ||
| 17.04. | Hautkrebsbehandlung: Medicus Pharma beantragt Orphan-Drug-Status | 8 | Investing.com Deutsch | ||
| 17.04. | Medicus Pharma Ltd: Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect in Gorlin Syndrome | 1.472 | GlobeNewswire (Europe) | PHILADELPHIA, April 17, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs... ► Artikel lesen | |
| 15.04. | Medicus Pharma Ltd: Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression | 5 | GlobeNewswire (USA) | ||
| 15.04. | EXCLUSIVE: Penny Stock Medicus Pharma Findings Support Potential In Women's Health Pipeline | 1 | Benzinga.com | ||
| 11.04. | New to The Street to Broadcast on Fox Business on Monday, April 13, Featuring Virtuix Holdings, Medicus Pharma, YY Group Holdings, Vivos Therapeutics, and Stardust Power | 1.547 | ACCESS Newswire | The show will air as sponsored programming nationwide at 10:30 PM PST on Fox Business Network NEW YORK CITY, NY / ACCESS Newswire / April 11, 2026 / New to The Street, one of the longest-running U.S.... ► Artikel lesen | |
| 07.04. | New to The Street Signs Medicus Pharma Ltd. to Transformational 12-Part National Media Series Highlighting SkinJect and Teverelix Platforms | 388 | ACCESS Newswire | NEW YORK CITY, NY / ACCESS Newswire / April 7, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX), a precision-guided biotech and life sciences company advancing innovative therapeutic platforms, has entered... ► Artikel lesen | |
| 06.04. | Medicus Pharma Ltd: Medicus Pharma Submits Optimized Phase 2 Study Protocol to U.S. FDA for Teverelix in Acute Urinary Retention | 368 | GlobeNewswire (Europe) | PHILADELPHIA, April 06, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs... ► Artikel lesen | |
| 06.04. | EXCLUSIVE: Medicus Pharma Refines Trial Design To Cut Costs, Accelerate Development For Enlarged Prostate Patients | 2 | Benzinga.com | ||
| 01.04. | Medicus Pharma clarifies Phase 2 skin cancer study results | 3 | Investing.com | ||
| 01.04. | Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset | 2 | GlobeNewswire (USA) | ||
| 30.03. | Medicus Pharma Ltd: Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate | 206 | GlobeNewswire (Europe) | PHILADELPHIA, March 30, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs... ► Artikel lesen | |
| 26.03. | Medicus Pharma reports 80% response rate in skin cancer study | 3 | Investing.com | ||
| 26.03. | Medicus Pharma: Hautkrebsstudie zeigt 80 % Ansprechrate | 5 | Investing.com Deutsch | ||
| 26.03. | Medicus Pharma Ltd: Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan | 328 | GlobeNewswire (Europe) | PHILADELPHIA, March 26, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs... ► Artikel lesen | |
| 26.03. | Medicus Pharma Ltd. GAAP EPS of $2.74 | 5 | Seeking Alpha |
1 2 3 4 5 Weiter >>
92 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 22,755 | +1,11 % | Ihre wichtigsten Termine: Heute im Blick: SAP, Intel, Pfizer, Nestle, LVMH, American Express und Heineken! | © Foto: Bild von Andreas Lischka auf PixabayGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine... ► Artikel lesen | |
| GILEAD SCIENCES | 111,90 | +1,38 % | Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel | FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the successful completion of its previously announced acquisition of Arcellx, Inc. (Nasdaq: ACLX). Under the... ► Artikel lesen | |
| ELI LILLY | 796,40 | +9,22 % | Psychiatrie-Revolution? Emyria Limited baut globale Service-Schiene für Sponsoren wie Eli Lilly und Compass Pathways aus | ||
| VERTEX PHARMACEUTICALS | 367,60 | +1,38 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| EYEPOINT | 11,000 | 0,00 % | EyePoint, Inc.: EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026 | ||
| ACHIEVE LIFE SCIENCES | 3,600 | +1,12 % | Achieve Life Sciences Announces Appointment of Andrew D. Goldberg, MD, as Chief Executive Officer and to the Board of Directors | Achieve Names Two New Exemplary Healthcare Leaders to its Board of Directors New Leadership and Financing, up to $354 Million ($180 Million Upfront and $174 Million Dependent on the Exercise of Milestone... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 193,00 | 0,00 % | Weekly Buzz: FDA Okays AstraZeneca's Saphnelo Pen, EC Clears Crinetics Pharmaceuticals' Acromegaly Drug, Soligenix Slumps, Ligand Snaps Up XOMA Royalty | BASEL (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals in the US and Europe, acquisitions, and a few trial halts, alongside positive data readouts spanning multiple therapeutic... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 173,50 | +1,34 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA | Prescription Drug User Fee Act (PDUFA) date set for August 25, 2026
For U.S. media and investors only
DUBLIN, April 27, 2026 /PRNewswire/ -- Jazz Pharmaceuticals... ► Artikel lesen | |
| OPKO HEALTH | 0,890 | -6,81 % | OPKO Health, Inc.: OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results | MIAMI, April 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three months ended March 31, 2026. Highlights from the first... ► Artikel lesen | |
| UNITED THERAPEUTICS | 494,60 | +1,15 % | United Therapeutics Corporation to Present at Upcoming Investor Conferences | United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that company executives will provide an overview and update on the company during fireside chat sessions... ► Artikel lesen | |
| ROYALTY PHARMA | 42,840 | +1,07 % | Royalty Pharma, Johnson & Johnson Enter Co-funding Agreement To Advance Development Of JNJ-4804 | NEW BRUNSWICK (dpa-AFX) - Royalty Pharma plc (RPRX) announced a research and development co-funding agreement
with Johnson & Johnson for a total of $500 million in 2026 and 2027 to advance... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 23,900 | -1,24 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026 | ||
| BRIDGEBIO PHARMA | 61,17 | +0,67 % | BridgeBio Pharma, Inc.: BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET | ||
| TG THERAPEUTICS | 28,800 | 0,00 % | TG Therapeutics, Inc.: TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI | Phase 3 trial evaluated two subcutaneous BRIUMVI dosing regimens; administration every 2 months or every 3 months Top-line data expected year-end 2026/ first quarter 2027 NEW YORK, April 15, 2026... ► Artikel lesen | |
| CORBUS PHARMACEUTICALS | 8,300 | +1,10 % | Clean Energy Fuels appoints Clay Corbus as CEO |
MEDICUS PHARMA LTD gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 0,282 Euro und damit -2,69 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDICUS PHARMA LTD finden Sie auf Wallstreet Online.